BACKGROUND: Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby promoting plaque formation. The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients. METHODS: SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 AD patients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years). RESULTS: Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4). CONCLUSION: Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients. Copyright 2008 S. Karger AG, Basel.
BACKGROUND:Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby promoting plaque formation. The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients. METHODS:SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 ADpatients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years). RESULTS: Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4). CONCLUSION: Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients. Copyright 2008 S. Karger AG, Basel.
Authors: Matthew Zabel; Matthew Schrag; Claudius Mueller; Weidong Zhou; Andrew Crofton; Floyd Petersen; April Dickson; Wolff M Kirsch Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Yaoyang Zhang; Michaela D Filiou; Stefan Reckow; Philipp Gormanns; Giuseppina Maccarrone; Melanie S Kessler; Elisabeth Frank; Boris Hambsch; Florian Holsboer; Rainer Landgraf; Christoph W Turck Journal: Mol Cell Proteomics Date: 2011-08-23 Impact factor: 5.911
Authors: Szilvia Veszelka; Judit Laszy; Tamás Pázmány; László Németh; Izabella Obál; László Fábián; Gábor Szabó; Csongor S Abrahám; Mária A Deli; Zoltán Urbányi Journal: Eur J Microbiol Immunol (Bp) Date: 2013-11-21
Authors: Gloria C Chi; Annette L Fitzpatrick; Monisha Sharma; Nancy S Jenny; Oscar L Lopez; Steven T DeKosky Journal: J Gerontol A Biol Sci Med Sci Date: 2017-06-01 Impact factor: 6.053